Table 3.
Univariate and multivariate binary logistical regression for AR
| Variable | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |
| Recipient age (yr) | 0.99 | 0.97–1.007 | 0.1 | |||
| Donor gender: female | 1.31 | 0.72–2.36 | 0.37 | |||
| Child to mother or husband to wife versus other types of donors | 1.19 | 0.54–2.64 | 0.66 | |||
| Time on dialysis (mo) | 1.001 | 0.99–1.007 | 0.79 | |||
| Transplant number >1 versus 1 | 1.49 | 0.79–2.79 | 0.22 | |||
| Induction treatment: rATG | 1.32 | 0.75–2.30 | 0.33 | |||
| CNI-free IS regimen: yes | 1.65 | 0.31–8.71 | 0.55 | |||
| Desensitization therapy: yes | 2.88 | 1.19–6.98 | 0.019 | 2.68 | 0.49–14.85 | 0.26 |
| CDC-XM + prior to desensitization | 2.77 | 0.45–16.94 | 0.27 | |||
| HLA allele mismatches | 1.01 | 0.84–1.21 | 0.93 | |||
| Class I | 1.082 | 0.82–1.42 | 0.57 | |||
| Class II | 1.12 | 0.75–1.69 | 0.55 | |||
| HLA eplet mismatches | ||||||
| Class I (A, B) | 1.012 | 0.966–1.060 | 0.61 | |||
| Class II: DR | 1.042 | 1.001–1.084 | 0.043 | 1.02 | 0.98–1–07 | 0.24 |
| DQ | 1.022 | 0.986–1.060 | 0.22 | |||
| CDC-PRA > 20 % | 2.08 | 0.96–4.51 | 0.06 | 1.18 | 0.35–3.99 | 0.79 |
| CDC-PRA > 80% | 4.35 | 1.06–17.89 | 0.042 | 3.01 | 0.45–20.3 | 0.26 |
| FC-XM anti T or B+ | 3.99 | 1.48–10.79 | 0.006 | 1.53 | 0.28–8.36 | 0.62 |
| DSA+ | 5.00 | 2.29–10.88 | <0.001 | 1.89 | 0.41–8.82 | 0.41 |
| DSA-C3d+ | 9.77 | 3.51–27.20 | <0.001 | 6.64 | 1.14–36.56 | 0.038 |
| DSA MFI > 6190a | 10.59 | 3.54–31.73 | <0.001 | 7.54 | 1.11–50.85 | 0.038 |
| FC-XM+/DSA+/b | 4.45 | 1.50–13.17 | 0.007 | 3.59 | 0.78–16.51 | 0.10 |
| FC-XM+/DSA-C3d+b | 6.64 | 1.81–24.26 | 0.004 | 4.94 | 0.98–24.81 | 0.05 |
CDC-XM, complement-dependent cytotoxicity crossmatch; CDC-PRA, complement-dependent cytotoxicity panel-reactive antibody; CI, confidence interval; CNI, calcineurin inhibitor; DSA, donor-specific antibody (solid phase assay); DSA-C3d, C3d-binding donor-specific antibody; FC-XM, flow cytometry crossmatch; MFI, mean fluorescence intensity; OR, odds ratio; rATG, rabbit anti-thymocyte globulin (Thymoglobulin®).
In the multivariate model for acute rejection evaluating the impact of each test individually (adjusted for desensitization therapy and human leukocyte antigen [HLA] DR-eplet mismatches), DSA+ also appears as an independent variable (OR = 5.1, 95% CI = 1.81–14.41, P = 0.002). Both DSA-C3d+ and DSA MFI > 6190 are independently correlated (OR = 12.0, 95% CI = 2.98–48.34, P < 0.001; OR = 15.6, 95% CI = 2.97–81.88, P = 0.001, respectively).
Analysis adjusted for desensitization therapy, HLA-DR eplet mismatches, CDC-PRA > 20%, CDC-PRA > 80%, FC-XM+, DSA+.
Analysis adjusted for desensitization therapy, HLA-DR eplet mismatches, CDC-PRA > 20%, CDC-PRA > 80%.